Results 51 to 60 of about 1,816 (169)

Treatment of the chronic hepatitis C complicated by mixed cryoglobulinemia with direct-acting antiviral agents

Журнал инфектологии, 2018
The aim of the study was to evaluate clinical, immunologic and anti-viral efficacy of antiviral therapy (АVT) with drugs of the direct antiviral action (DAA) of the chronic hepatitis C (CHC) complicated with secondary mixed cryoglobulinemia in small ...
N. V. Dunaeva, E. Yu. Kolpashchikova, S. Yu. Romanova, S. N. Kizhlo, S. V. Lapin, D. A. Gusev   +5 more
doaj   +1 more source

Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices

Pharmaceuticals, 2022
The inhibition of P-glycoprotein (ABCB1) could lead to increased drug plasma concentrations and hence increase drug toxicity. The evaluation of a drug’s ability to inhibit ABCB1 is complicated by the presence of several transport-competent sites within ...
Martin Huličiak, Ivan Vokřál, Ondřej Holas, Ondřej Martinec, František Štaud, Lukáš Červený   +5 more
doaj   +1 more source

Cell Type‐Specific mTORC1 Signaling and Translational Control in Synaptic Plasticity and Memory

Journal of Neurochemistry, Volume 169, Issue 11, November 2025.
The formation of long‐term memories depends on de novo protein synthesis, a process tightly regulated by the mechanistic/mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. mTORC1 plays a central role in promoting mRNA translation in the central nervous system.
Ziying Huang, Niaz Mahmood, Shane Wiebe, Arkady Khoutorsky, Jean‐Claude Lacaille, Nahum Sonenberg   +5 more
wiley   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, Volume 5, Issue 9, September 2025.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Clearance of Hepatitis C Viremia During Direct‐Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism

Alimentary Pharmacology &Therapeutics, Volume 62, Issue 2, Page 146-158, July 2025.
HCV clearance during direct‐acting antiviral therapy rapidly increases serum lipids and lipoproteins, potentially elevating cardiovascular risk. These metabolic changes, mediated by genes regulating hepatic lipogenesis, suggest that lipid levels should be closely monitored post‐SVR to assess long‐term cardiovascular implications.
Zahra Sarrafan‐Chaharsoughi, Varun Takyar, Sungyoung Auh, Gavin Nee, Ahmad Alawad, Brent S. Abel, Devika Kapuria, Colleen Byrnes, Anna Wolska, David E. Kleiner, Robert Shamburek, Alan T. Remaley, Marc G. Ghany   +12 more
wiley   +1 more source

Multivariate logistic regression analysis to identify factors associated with liver injuries in patients with genotype 1b HCV receiving daclatasvir plus asunaprevir therapy.

, 2018
Multivariate logistic regression analysis to identify factors associated with liver injuries in patients with genotype 1b HCV receiving daclatasvir plus asunaprevir therapy.
Kayoko Sugawara (5848991), Yukinori Imai (5849006), Nobuaki Nakayama (5849003), Masamitsu Nakao (5848994), Mie Inao (5849000), Satoshi Mochida (156566), Jun-ichi Kouyama (661243), Daisuke Motoya (5848997), Yoshihito Uchida (661242), Kayoko Naiki (661244), Tomoaki Tomiya (479370)   +10 more
core   +1 more source

Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C

Virology Journal, 2017
Background Direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the efficacy of DAAs. The aim of this
Jung Hwan Yu, Jung Il Lee, Kwan Sik Lee, Ja Kyung Kim   +3 more
doaj   +1 more source

Strategies for Biomethane Purification: A Critical Review and New Approaches

GCB Bioenergy, Volume 17, Issue 5, May 2025.
ABSTRACT The global shift towards clean energy emphasizes waste valorization as a key to achieving sustainable development goals. Biomethane production from organic waste not only converts waste to energy but also reduces greenhouse gas emissions. The growth trajectory of sustainability and environmental protection highlights the significance of energy
Lolo Errol Molatudi, Thokozani Justin Kunene, Tebogo Mashifana   +2 more
wiley   +1 more source

The demographic and clinical features of 278 patients with genotype 1b hepatitis C virus (HCV) infection receiving daclatasvir (DCV) plus asunaprevir (ASV) therapy.

, 2018
The demographic and clinical features of 278 patients with genotype 1b hepatitis C virus (HCV) infection receiving daclatasvir (DCV) plus asunaprevir (ASV) therapy.
Kayoko Sugawara (5848991), Yukinori Imai (5849006), Nobuaki Nakayama (5849003), Masamitsu Nakao (5848994), Mie Inao (5849000), Satoshi Mochida (156566), Jun-ichi Kouyama (661243), Daisuke Motoya (5848997), Yoshihito Uchida (661242), Kayoko Naiki (661244), Tomoaki Tomiya (479370)   +10 more
core   +1 more source

Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT This multicentre study investigated the dynamics of thrombospondin 2 (TSP2) levels during direct‐acting antiviral (DAA) therapy in hepatitis C virus (HCV) infected patients and evaluated TSP2's potential as a predictive marker for hepatocellular carcinoma (HCC).
Takanobu Iwadare, Takefumi Kimura, Ayumi Sugiura, Taiki Okumura, Shun‐ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Tomoo Yamazaki, Satoru Joshita, Naoki Tanaka, Takeji Umemura   +10 more
wiley   +1 more source